Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5 482 M
EBIT 2016 1 387 M
Net income 2016 -2 082 M
Debt 2016 5 310 M
Yield 2016 0,90%
Sales 2017 4 870 M
EBIT 2017 1 060 M
Net income 2017 466 M
Debt 2017 2 696 M
Yield 2017 0,85%
P/E ratio 2016 -
P/E ratio 2017 24,89
EV / Sales2016 2,74x
EV / Sales2017 2,55x
Capitalization 9 722 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
05/11Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
04/25 PERRIGO CO PLC : Entry into a Material Definitive Agreement, Results of Operatio..
03/29 PERRIGO CO PLC : Completion of Acquisition or Disposition of Assets, Financial S..
03/17 PERRIGO CO PLC : Notice of Delisting or Failure to Satisfy a Continued Listing R..
03/16 PERRIGO CO PLC : Entry into a Material Definitive Agreement, Creation of a Direc..
03/06 PERRIGO COMPANY PLC ORDINARY SHARES : PRGO) Becomes The Latest Pharma Investiga..
03/02 PERRIGO COMPANY PLC ORDINARY SHARES : PRGO) Drug Gets FDA Approval
03/01 PERRIGO COMPANY PLC : Pawar Law Group Announces Investigation of Securities Clai..
03/01 EpiPen maker Mylan forecasts strong 2017; shares jump
03/01 PERRIGO COMPANY PLC ORDINARY SHARES : PRGO) Sells Rights To Tysabri
03/01 PERRIGO COMPANY PLC : ex-dividend day
More news
Sector news : Pharmaceuticals - NEC
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
04/25DJNasdaq Composite Tops 6000 for First Time
04/25DJASTRAZENECA : Lung Cancer Treatment Approved in EU
04/25DJELI LILLY AND : Working to Cut Costs
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 18
Average target price 78,8 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John T. Hendrickson Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY9 722
JOHNSON & JOHNSON7.13%334 605
ROCHE HOLDING LTD.10.49%223 016
PFIZER INC.3.88%201 045
NOVARTIS AG2.16%199 772
MERCK & CO., INC.5.83%170 797
More Results